KRAS and pancreatic ductal adenocarcinoma: The G12C substitution in KRAS also happens, as has been reported, in 3% of all colorectal cancers and 2% of all pancreatic ductal adenocarcinomas [8,9], while, based on TCGA database, the incidence of G12C substitution in colon cancers reaches 11% (Figure 1).